GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Change In Receivables

InNexus Biotechnology (InNexus Biotechnology) Change In Receivables : $0.00 Mil (TTM As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Change In Receivables?

InNexus Biotechnology's change in receivables for the quarter that ended in Mar. 2011 was $0.00 Mil. It means InNexus Biotechnology's Accounts Receivable stayed the same from Dec. 2010 to Mar. 2011 .

InNexus Biotechnology's change in receivables for the fiscal year that ended in Jun. 2010 was $0.01 Mil. It means InNexus Biotechnology's Accounts Receivable declined by $0.01 Mil from Jun. 2009 to Jun. 2010 .

InNexus Biotechnology's Accounts Receivable for the quarter that ended in Mar. 2011 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. InNexus Biotechnology's liquidation value for the three months ended in Mar. 2011 was $-9.78 Mil.


InNexus Biotechnology Change In Receivables Historical Data

The historical data trend for InNexus Biotechnology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Change In Receivables Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 0.01 -0.04 0.01 0.01

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InNexus Biotechnology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology  (GREY:IXSBF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

InNexus Biotechnology's Days Sales Outstanding for the quarter that ended in Mar. 2011 is calculated as:

2. In Ben Graham's calculation of liquidation value, InNexus Biotechnology's accounts receivable are only considered to be worth 75% of book value:

InNexus Biotechnology's liquidation value for the quarter that ended in Mar. 2011 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.032-9.811+0.75 * 0+0.5 * 0
=-9.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology Change In Receivables Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines